Literature DB >> 16252263

t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma.

James A L Fenton1, Ed Schuuring, Sharon L Barrans, Alison H Banham, Sara J Rollinson, Gareth J Morgan, Andrew S Jack, J Han J M van Krieken, Philip M Kluin.   

Abstract

Strong expression of Forkhead box-P1 (FOXP1), a winged-helix transcription factor, has been identified as an independent prognostic factor in diffuse large B-cell lymphoma (DLBCL). However, possible mechanisms of deregulation of this gene, on 3p14.1, have yet to be elucidated. We have identified a breakpoint at the IGA1 gene in the immunoglobulin heavy chain (IGH) locus at 14q32 that was juxtaposed to the FOXP1 gene locus in a gastric DLBCL that showed strong expression of FOXP1. This may be one possible mechanism of deregulating FOXP1 expression by placing it under the control of IGH enhancers.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16252263     DOI： 10.1002/gcc.20278

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN： 1045-2257            Impact factor:   5.006


  16 in total

1.  Prognostic markers and gene abnormalities in subgroups of diffuse large B-cell lymphoma: single center experience.

Authors:  Petra Korać; Mara Dominis
Journal:  Croat Med J       Date:  2008-10       Impact factor: 1.351

2.  Solution structure and backbone dynamics of the DNA-binding domain of FOXP1: insight into its domain swapping and DNA binding.

Authors:  Yuan-Ping Chu; Chia-Hao Chang; Jia-Hau Shiu; Yao-Tsung Chang; Chiu-Yueh Chen; Woei-Jer Chuang
Journal:  Protein Sci       Date:  2011-04-11       Impact factor: 6.725

3.  FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells.

Authors:  Martine van Keimpema; Leonie J Grüneberg; Michal Mokry; Ruben van Boxtel; Jan Koster; Paul J Coffer; Steven T Pals; Marcel Spaargaren
Journal:  Blood       Date:  2014-09-29       Impact factor: 22.113

4.  FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging.

Authors:  Hanjun Li; Pei Liu; Shuqin Xu; Yinghua Li; Joseph D Dekker; Baojie Li; Ying Fan; Zhenlin Zhang; Yang Hong; Gong Yang; Tingting Tang; Yongxin Ren; Haley O Tucker; Zhengju Yao; Xizhi Guo
Journal:  J Clin Invest       Date:  2017-02-27       Impact factor: 14.808

Review 5.  Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists.

Authors:  Chris M Bacon; Ming-Qing Du; Ahmet Dogan
Journal:  J Clin Pathol       Date:  2006-09-01       Impact factor: 3.411

6.  Downregulation of FOXP1 is required during germinal center B-cell function.

Authors:  Ainara Sagardoy; Jose I Martinez-Ferrandis; Sergio Roa; Karen L Bunting; María Angela Aznar; Olivier Elemento; Rita Shaknovich; Lorena Fontán; Vicente Fresquet; Ignacio Perez-Roger; Eloy F Robles; Linde De Smedt; Xavier Sagaert; Ari Melnick; Jose A Martinez-Climent
Journal:  Blood       Date:  2013-04-11       Impact factor: 22.113

Review 7.  Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas.

Authors:  Richard J Bende; Febe van Maldegem; Carel J M van Noesel
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

8.  The forkhead transcription factor FOXP1 represses human plasma cell differentiation.

Authors:  Martine van Keimpema; Leonie J Grüneberg; Michal Mokry; Ruben van Boxtel; Menno C van Zelm; Paul Coffer; Steven T Pals; Marcel Spaargaren
Journal:  Blood       Date:  2015-08-19       Impact factor: 22.113

9.  Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas.

Authors:  Alexandar Tzankov; Philip Went; Stephan Dirnhofer
Journal:  Biomark Insights       Date:  2007-11-11

10.  NotI microarrays: novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer.

Authors:  Vladimir Kashuba; Alexey A Dmitriev; George S Krasnov; Tatiana Pavlova; Ilya Ignatjev; Vasily V Gordiyuk; Anna V Gerashchenko; Eleonora A Braga; Surya P Yenamandra; Michael Lerman; Vera N Senchenko; Eugene Zabarovsky
Journal:  Int J Mol Sci       Date:  2012-10-18       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.